Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy

JAMA. 2004 Oct 20;292(15):1831-8. doi: 10.1001/jama.292.15.1831.


Context: Data are limited regarding the risks and benefits of thrombolytic therapy for acute ischemic stroke outside of clinical trials.

Objective: To investigate predictors of in-hospital mortality in patients with ischemic stroke treated with intravenous tissue plasminogen activator (tPA) within a pooled analysis of large German stroke registers.

Design and setting: Prospective, observational cohort study conducted at 225 community and academic hospitals throughout Germany cooperating within the German Stroke Registers Study Group.

Patients: A total of 1658 patients with acute ischemic stroke who were admitted to study hospitals between 2000 and 2002 and were treated with tPA.

Main outcome measure: In-hospital mortality.

Results: One hundred sixty-six patients (10%) who received tPA died during hospitalization, with 67.5% of these deaths occurring within 7 days. Factors predicting in-hospital death after tPA use were older age (for each 10-year increment in age, adjusted odds ratio [OR], 1.6; 95% confidence interval [CI], 1.3-1.9) and altered level of consciousness (adjusted OR, 3.4; 95% CI, 2.4-4.7). The overall rate of symptomatic intracranial hemorrhage was 7.1% and increased with age. One or more serious complications was observed in 27.2% of all patients and in 83.9% of patients who died after tPA treatment. An inverse relation between the number of patients treated with tPA in the respective hospital and the risk of in-hospital death was observed (adjusted OR, 0.97; 95% CI, 0.96-0.99 for each additional patient treated with tPA per year).

Conclusion: In patients with ischemic stroke who are treated with tPA, disturbances of consciousness and increasing age are associated with increased in-hospital mortality.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Brain Ischemia
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Hospital Mortality*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk
  • Stroke / drug therapy*
  • Stroke / mortality*
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use*


  • Fibrinolytic Agents
  • Tissue Plasminogen Activator